Inorganic Chemistry
Article
1 Hz, 1H), 5.55 (d, J = 8 Hz, 1H), 5.32−5.14 (m, 4H), 5.01 (d, J = 8
Hz, 1H), 3.28−3.17 (m, 1H), 3.17−3.01 (m, 3H), 2.94−2.83 (m,
2H), 2.83−2.71 (m, 2H), 1.37−1.25 (m, 2H), 1.25−1.10 (m, 2H).
13C NMR (100 MHz, CDCl3): δ 161.3, 160.4, 160.3, 157.8, 157.7,
142.7, 142.4, 142.3, 138.0, 133.1, 133.0, 132.9, 130.1, 129.94, 129.85,
129.3, 129.2, 129.0, 128.30, 128.27, 128.2, 123.3, 123.2, 122.4, 104.6,
102.2, 79.2, 79.1, 78.9. ESI-HRMS: m/z 835.3053 ([M + Na]+)
(calcd 835.3062).
washed with 10% citric acid(aq) (20 mL) and 10% NaHCO3(aq) (20
mL). The organic layer was dried over anhydrous MgSO4(s) and
concentrated under reduced pressure. The crude product was then
purified by flash chromatography over silica eluting with a 40% ethyl
acetate/60% hexanes mixture to yield the protected cap 16 as a white
1
foaming liquid (1.89 g, 90%). H NMR (400 MHz, CDCl3): δ 5.53
(br, 1H), 5.42 (br, 1H), 5.21 (br, 1H), 3.90 (br, 2H), 3.41 (br, 2H),
3.32 (br, 2H), 3.24 (br, 2H), 1.42−1.31 (m, 27H). 13C NMR (100
MHz, CDCl3): δ 169.8, 156.2, 155.9, 155.7, 79.6, 79.4, 79.2, 47.4,
46.3, 42.0, 38.8, 28.23, 28.22, 28.20. ESI-HRMS: m/z 483.2794 ([M
+ Na]+) (calcd 483.2789).
1-Hydroxy-N,N-bis[2-(1-hydroxy-6-oxo-1,6-dihydropyri-
dine-2-carboxamido)ethyl]-6-oxo-1,6-dihydropyridine-2-car-
boxamide (2,2-Li-HOPO, 14). The protected ligand 12 (500 mg,
0.638 mmol) was dissolved in a 1:1 (v/v) mixture of glacial acetic acid
and HBr(aq) (37%, 10 mL). The reaction mixture was stirred at room
temperature for 6 h. The volatiles were then removed under reduced
pressure, and the residue was purified by flash chromatography over
modified silica eluting with a gradient of 100% H2O to 5% CH3OH/
95% H2O to yield the deprotected ligand 14 as a beige foaming liquid
1-(Benzyloxy)-N-(2-{2-[1-(benzyloxy)-6-oxo-1,6-dihydropyr-
idine-2-carboxamido]-N-{2-[1-(benzyloxy)-6-oxo-1,6-dihydro-
pyridine-2-carboxamido]ethyl}acetamido}ethyl)-6-oxo-1,6-di-
hydropyridine-2-carboxamide (17). Trifluoroacetic acid (10 mL)
was added to a solution of the protected cap 16 (500 mg, 1.09 mmol)
in CH2Cl2 (10 mL). The reaction mixture was stirred at room
temperature for 1 h. The volatiles were removed under reduced
pressure to yield the deprotected ligand cap that was used
immediately without further purification. The benzyl-protected N-
hydroxysuccinimide-activated 1,2-hydroxypyridinone podand [8,
HOPO(Bn)-OSu, 1.11 g, 3.26 mmol] was added to a solution of
the deprotected ligand cap in CH3CN (10 mL). Triethylamine (697
μL, 4.36 mmol) was then slowly added to the reaction mixture, which
was stirred at room temperature for 6 h. The reaction mixture was
then washed with 10% NaHCO3(aq) (10 mL), dried over anhydrous
MgSO4(s), and concentrated under reduced pressure to yield a
viscous liquid. The crude product was further purified by flash
chromatography over silica eluting with a 4% CH3OH/96% CH2Cl2
mixture to yield the protected ligand 17 as a foam (780 mg, 85%). 1H
NMR (500 MHz, CDCl3): δ 7.80 (br, 1H), 7.51−7.45 (m, 2H),
7.44−7.36 (m, 7H), 7.34−7.28 (m, 6H), 7.25−7.18 (m, 4H), 7.17−
7.10 (m, 2H), 6.62 (d, J = 9 Hz, 1H), 6.54 (dd, J1 = 8 Hz, J2 = 1 Hz,
2H), 6.29 (d, J = 7 Hz, 1H), 6.25 (d, J = 7 Hz, 1H), 6.19 (d, J = 7 Hz,
1H), 5.24 (s, 4H), 5.22 (s, 2H), 3.86 (d, J = 5 Hz, 2H), 3.35 (br, 4H),
3.31−3.25 (m, 2H), 3.23−3.18 (m, 2H). 13C NMR (125 MHz,
CDCl3): δ 168.6, 161.0, 160.7, 159.8, 158.4, 158.3, 142.7, 142.4,
141.7, 138.10, 138.06, 137.9, 133.3, 133.2, 133.0, 130.2, 130.1, 130.0,
129.34, 129.26, 128.51, 128.50, 128.4, 124.1, 123.6, 106.6, 105.7,
105.4, 79.2, 79.0, 77.3, 77.2, 77.0, 76.7, 46.4, 45.8, 41.3, 38.4, 38.2.
ESI-HRMS: m/z 864.3072 ([M + Na]+) (calcd 864.2964).
1
(295 mg, 90%). H NMR (400 MHz, CD3OD): δ 7.54−7.42 (m,
3H), 6.75 (dd, J1 = 9 Hz, J2 = 1 Hz, 2H), 6.73−6.63 (m, 3H), 6.47
(dd, J1 = 7 Hz, J2 = 1 Hz, 1H), 3.93−3.83 (m, 2H), 3.81−3.67 (m,
2H), 3.67−3.55 (br, 4H). 13C NMR (100 MHz, CD3OD): δ 164.4,
162.9, 162.7, 160.5, 160.3, 160.1, 142.4, 142.0, 141.5, 139.9, 139.0,
138.7, 121.0, 120.9, 120.8, 109.3, 108.8, 106.3, 49.2, 45.9, 39.1, 38.5.
ESI-HRMS: m/z 537.1346 ([M + Na]+) (calcd 537.1340).
1-Hydroxy-N,N-bis[3-(1-hydroxy-6-oxo-1,6-dihydropyri-
dine-2-carboxamido)propyl]-6-oxo-1,6-dihydropyridine-2-
carboxamide (3,3-Li-HOPO, 15). The protected ligand 13 (500
mg, 0.616 mmol) was dissolved in a 1:1 (v/v) mixture of glacial acetic
acid and HBr(aq) (37%, 10 mL). The reaction mixture was stirred at
room temperature for 6 h. The volatiles were then removed under
reduced pressure, and the residue was purified by flash chromatog-
raphy over modified silica eluting with a gradient of 100% H2O to 5%
CH3OH/95% H2O to yield the deprotected ligand 15 as a beige
1
foaming liquid (287 mg, 86%). H NMR (500 MHz, CD3OD): δ
7.51−7.40 (m, 3H), 6.71 (dd, J1 = 9 Hz, J2 = 1 Hz, 2H), 6.64 (dd, J1 =
7 Hz, J2 = 1 Hz, 1H), 6.57 (dd, J1 = 9 Hz, J2 = 1 Hz, 1H), 6.54 (dd, J1
= 7 Hz, J2 = 1 Hz, 1H), 6.38 (dd, J1 = 7 Hz, J2 = 1 Hz, 1H), 3.61 (br,
2H), 3.49−3.39 (m, 2H), 3.33 (br, 1H), 3.30−3.25 (m, 3H), 2.00−
1.93 (m, 2H), 1.93−1.78 (m, 2H). 13C NMR (125 MHz, CD3OD): δ
163.7, 162.6, 162.5, 160.3, 160.2, 160.0, 142.8, 142.2, 141.7, 139.9,
139.1, 138.7, 120.9, 120.7, 120.6, 108.9, 108.5, 105.7, 47.7, 43.6, 38.4,
38.2, 29.2, 27.9. ESI-HRMS: m/z 565.1699 ([M + Na]+) (calcd
565.1653).
EuIII-2,2-Li-HOPO (3). The deprotected ligand 14 (20 mg, 0.039
mmol) and EuCl3·6H2O (14 mg, 0.039 mmol) were dissolved in a 1:1
(v/v) mixture of CH3OH and Milli-Q water (5 mL). Pyridine (31 μL,
0.39 mmol) was subsequently added to the reaction mixture, which
was stirred at 60 °C for 15 h. The reaction mixture was allowed to
cool to room temperature. The suspension was filtered and rinsed
with methanol. The residue was further dried under reduced pressure
to yield the final EuIII complex 3 as a beige powder (22 mg, 95%).
ESI-HRMS: m/z 695.0479 ([M + CH3OH − H]−) (calcd 695.0606),
m/z 709.0388 ([M + COOH2 − H]−) (calcd 709.0399).
N-(2-{Bis[2-(1-hydroxy-6-oxo-1,6-dihydropyridine-2-
carboxamido)ethyl]amino}-2-oxoethyl)-1-hydroxy-6-oxo-1,6-
dihydropyridine-2-carboxamide (2,2-Gly-HOPO, 18). The
protected ligand 17 (500 mg, 0.594 mmol) was dissolved in a 1:1
(v/v) mixture of glacial acetic acid and HBr(aq) (37%, 10 mL). The
reaction mixture was stirred at room temperature for 6 h, after which
the volatiles were removed under reduced pressure. The residue was
then purified by flash chromatography over modified silica eluting
with a gradient of 100% H2O to 5% CH3OH/95% H2O to yield the
1
EuIII-3,3-Li-HOPO (4). The deprotected ligand 15 (20 mg, 0.037
mmol) and EuCl3·6H2O (14 mg, 0.037 mmol) were dissolved in a 1:1
(v/v) mixture of CH3OH and Milli-Q water (5 mL). Pyridine (30 μL,
0.37 mmol) was subsequently added to the reaction mixture, which
was stirred at 60 °C for 15 h. The reaction mixture was allowed to
cool to room temperature. The suspension was filtered and rinsed
with methanol. The residue was further dried under reduced pressure
to yield the final EuIII complex 4 as a beige powder (23 mg, 88%).
ESI-HRMS: m/z 715.0605 ([M + Na]+) (calcd 715.0633).
tert-Butyl [2-(Bis{2-[(tert-butoxycarbonyl)amino]ethyl}-
amino)-2-oxoethyl]carbamate (16). Triethylamine (1.27 mL,
9,14 mmol) was added to a solution of (tert-butoxycarbonyl)glycine
(Boc-Gly-OH, 800 mg, 4.57 mmol), di-tert-butyl [azanediylbis-
(ethane-2,1-diyl)]dicarbamate (1.39 g, 4.57 mmol), and 2-(1H-
benzotriazole-1-yl)-1,1,3,3-tetramethylaminium tetrafluoroborate
(TBTU, 1.47 mg, 4.57 mmol) in anhydrous CH2Cl2 (25 mL). The
reaction mixture was stirred at room temperature for 12 h and then
deprotected ligand, a beige foaming liquid 18 (305 mg, 90%). H
NMR (400 MHz, D2O): δ 7.51−7.39 (m, 3H), 6.77−6.52 (m, 6H),
4.30 (br, 2H), 3.64 (br, 6H), 3.56 (br, 2H). 13C NMR (100 MHz,
D2O): δ 169.9, 162.3, 162.1, 161.7, 159.69, 159.66, 159.62, 140.1,
139.9, 139.2, 138.9, 138.6, 120.9, 120.7, 109.5, 108.33, 108.30, 45.9,
44.7, 41.5, 37.5, 37.3. ESI-HRMS: m/z 572.1798 ([M + H]+) (calcd
572.1736).
EuIII-2,2-Gly-HOPO (5). The deprotected ligand 18 (20 mg, 0.035
mmol) and EuCl3·6H2O (13 mg, 0.035 mmol) were dissolved in a 1:1
mixture of CH3OH (2.5 mL) and Milli-Q water (2.5 mL). Pyridine
(28 μL, 0.35 mmol) was subsequently added to the reaction mixture,
which was stirred at 60 °C for 15 h. The reaction mixture was allowed
to cool to room temperature. The suspension was filtered and rinsed
with methanol. The residue was further dried under reduced pressure
to yield the final EuIII complex 5 as a beige powder (21 mg, 84%).
ESI-HRMS: m/z 744.0604 ([M + Na]+) (calcd 744.0535).
J
Inorg. Chem. XXXX, XXX, XXX−XXX